NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased…
Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped…
– Initial interim safety, tolerability, biomarker, and preliminary efficacy data expected in Q1 2026 –MIAMI, July 31, 2025 (GLOBE NEWSWIRE)…
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and…
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025…
Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti®…
Investment Opens for up to US$5.0 Million through a Regulation D 506(c) Offering to Fund Growth and Path to Possible…
SOUTHAMPTON, England, July 30, 2025 /PRNewswire/ -- MODERNISED (NIHR207538), a multi-site UK clinical study has passed a key milestone: over 450…
TORONTO, July 30, 2025 /PRNewswire/ -- In this free webinar, discover practical use cases of AI in clinical trials —…
SINGAPORE, July 30, 2025 /PRNewswire/ -- Emerald Clinical Trials, a leading global clinical research organization, today announced a leadership transition.…